Epistem Holdings Plc, the biotechnology and personalised medicine company, announced anupdate regarding the Genedrive collaboration with Xcelris Laboratories. The first round of TB clinical studies has been successfully completed. Epistem and Xcelris are preparing for commercial launch at the beginning of 2012.
The EHP share price has increased by 10% over the last year.
Epistem Holdings Plc is currently graded b by LCF Research. To learn more, follow the link.
